Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 11:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,566 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Single Food Clear all
Completed Phase 2 Interventional Results available

Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke

NCT00894803
View directory record Official record
Conditions
Ischemic Stroke, Stroke, Brain Infarction
Interventions
Eptifibatide, rt-PA
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 85 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
20
States / cities
Los Angeles, California • San Diego, California • Santa Monica, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2014 · Synced Oct 20, 2026, 11:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability Study of CC-292

NCT02433457
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CC-292, Oral Omeprazole (OMP)
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Oct 20, 2026, 11:21 AM EDT
Completed Phase 3 Interventional Results available

Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment

NCT01363011
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
E/C/F/TDF, COBI, ATV, DRV, NRTI
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Oct 20, 2026, 11:21 AM EDT
Completed Not applicable Interventional Results available

Cryovagotomy Diabetes Trial

NCT04276051
View directory record Official record
Conditions
Diabetes Type 2, Diabetes Mellitus, Obesity
Interventions
Cryoablation of the Vagus Nerve, Lifestyle Intervention
Device · Behavioral
Lead sponsor
Emory University
Other
Eligibility
22 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Atlanta, Georgia • Johns Creek, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 8, 2023 · Synced Oct 20, 2026, 11:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability, PK, ECG Effects, Food Effect, and Drug-drug Interaction (DDI) of Hormonal Contraceptives of PTI-428 in Healthy Female Volunteers

NCT02846142
View directory record Official record
Conditions
Healthy Volunteer
Interventions
PTI-428, Placebo, ethinyl estradiol and levonorgestrel
Drug · Other
Lead sponsor
Proteostasis Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Oct 20, 2026, 11:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of OZ439 in Healthy Male and Female Subjects

NCT00928083
View directory record Official record
Conditions
Malaria Falciparum, Malaria Vivax, Healthy Volunteers
Interventions
OZ439 50mg API capsules, OZ439 200mg API capsules, OZ439 400mg aqueous dispersion, OZ439 800mg aqueous dispersion, OZ439 100mg API capsules, OZ439 400mg API capsules, OZ439 1600mg aqueous dispersion, OZ439 800mg API capsules, OZ439 1200mg API capsules, Placebo, OZ439 200mg aqueous dispersion
Drug
Lead sponsor
Medicines for Malaria Venture
Other
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Oct 20, 2026, 11:21 AM EDT
Terminated Phase 3 Interventional Results available

An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE

NCT04912856
View directory record Official record
Conditions
Epilepsy, Epilepsy in Children, Epilepsy; Seizure, Disease, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Epileptic Syndromes
Interventions
XEN496
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
1 Month to 6 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Oct 20, 2026, 11:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Dose Proportionality and Food Effect of Morphine Sulfate

NCT00994539
View directory record Official record
Conditions
Pain
Interventions
morphine sulfate
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 20, 2026, 11:21 AM EDT
Completed Not applicable Interventional

High Dose Vitamin A in Preventing Gastrointestinal GVHD in Participants Undergoing Donor Stem Cell Transplant

NCT03719092
View directory record Official record
Conditions
Allogeneic Hematopoietic Stem Cell Transplantation Recipient
Interventions
Vitamin A Compound, Best Practice
Dietary Supplement · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 20, 2026, 11:21 AM EDT
Completed Not applicable Interventional

Effects of Prebiotic Supplementation and Exercise on Inflammatory Markers, Vascular Function and Cognition in CKD

NCT03689569
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
Resistant starch, Exercise, Starch
Dietary Supplement · Behavioral
Lead sponsor
Springfield College
Other
Eligibility
30 Years to 75 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 20, 2026, 11:21 AM EDT
Completed Not applicable Interventional

Effect of High-Dose Guarana And Cancer-Related Fatigue

NCT03897556
View directory record Official record
Conditions
Cancer-related Fatigue
Interventions
Guarana herb, Usual Care
Dietary Supplement · Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 9, 2022 · Synced Oct 20, 2026, 11:21 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Different Viscous Foods and Liquids on Swallowing Sounds

NCT03024333
View directory record Official record
Conditions
Deglutition Disorder
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Oct 20, 2026, 11:21 AM EDT
Completed Not applicable Interventional

Development of Self-Regulation in Individuals With Type 2 Diabetes

NCT00941447
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dietary, Physical Activity, Self-Regulatory Approaches
Behavioral
Lead sponsor
The University of Tennessee, Knoxville
Other
Eligibility
21 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 20, 2026, 11:21 AM EDT
Completed Phase 1 Interventional

Baricitinib for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation

NCT04131738
View directory record Official record
Conditions
Graft-versus-host-disease, Graft Vs Host Disease
Interventions
Baricitinib
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 20, 2026, 11:21 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

EMPOWIR:Enhance the Metabolic Profile of Women With Insulin Resistance

NCT00618072
View directory record Official record
Conditions
Hyperinsulinemia, Insulin Resistance, Obesity
Interventions
metformin and rosiglitazone
Drug
Lead sponsor
New York Medical College
Other
Eligibility
35 Years to 55 Years · Female only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 28, 2014 · Synced Oct 20, 2026, 11:21 AM EDT
Not yet recruiting Not applicable Interventional

Optimization of Dietary Adherence in a Mobile Weight Loss Intervention

NCT07582536
View directory record Official record
Conditions
Overweight and/or Obesity
Interventions
Core, Switch to Simplified Diet Monitoring, Goal Autonomy/Planning, Just-in-time (JIT) Messaging, Coach Sessions
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 20, 2026, 11:21 AM EDT
Completed No phase listed Observational Results available

Multi-center Prospective Study to Evaluate Outcomes of the Moderate to Severely Calcified Coronary Lesions (MACE)

NCT01930214
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Percutaneous Coronary Intervention
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
34
States / cities
Little Rock, Arkansas • Glendale, California • Hartford, Connecticut + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Oct 20, 2026, 11:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fed Study of Rabeprazole Sodium Tablets 20 mg and Aciphex® Tablets 20 mg

NCT00649493
View directory record Official record
Conditions
Healthy
Interventions
Rabeprazole Sodium Tablets 20 mg, Aciphex® Tablets 20 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
8 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 20, 2026, 11:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Investigate Palbociclib (PD-0332991) Pharmacokinetics In Healthy Subjects Of Japanese Descent Relative To Healthy Non-Asian Subjects, And To Determine If Changes In Palbociclib Dose Result In Proportional Changes In Palbociclib Plasma Exposure In Japanese Subjects

NCT02059330
View directory record Official record
Conditions
Healthy
Interventions
Palbociclib 75mg, Palbociclib 125mg, Palbociclib 100mg, Palbociclib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 24, 2014 · Synced Oct 20, 2026, 11:21 AM EDT
Recruiting Phase 2 Interventional

Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

NCT01804634
View directory record Official record
Conditions
Refractory and/or Relapsed Metastatic Solid Tumors
Interventions
Cyclophosphamide, Fludarabine, low dose total body irradiation, Melphalan, Tacrolimus
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
1 Year to 50 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
3
States / cities
Baltimore, Maryland • The Bronx, New York • Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 20, 2026, 11:21 AM EDT
Terminated Phase 1 Interventional

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years

NCT05660265
View directory record Official record
Conditions
Hematologic Diseases, Anaemia, Sickle Cell
Interventions
GSK4172239D, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Miami, Florida • Tamarac, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 20, 2026, 11:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fed Study of Oxycodone Hydrochloride 30 mg Tablets and Roxicodone™ 30 mg Tablets

NCT00853736
View directory record Official record
Conditions
Healthy
Interventions
Roxicodone™ tablet 30 mg, Oxycodone hydrochloride tablet 30 mg
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 19, 2016 · Synced Oct 20, 2026, 11:21 AM EDT
Recruiting Not applicable Interventional

Testing Implementation Strategies to Scale-up a Multicomponent Continuum of Service Intervention for Families Involved in Systems With Parental Opioid and Methamphetamine Use

NCT07365293
View directory record Official record
Conditions
Substance Related Disorders
Interventions
Just Care for Families (JCFF), Just Care for Families (JCFF) App, Just Care for Families (JCFF) App Feedback
Behavioral
Lead sponsor
Chestnut Health Systems
Other
Eligibility
Not listed
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 20, 2026, 11:21 AM EDT
Active, not recruiting Phase 2 Interventional

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

NCT04557449
View directory record Official record
Conditions
Liposarcoma, Prostate Cancer, Breast Neoplasms, Adenocarcinoma of Lung
Interventions
PF-07220060, Letrozole, Fulvestrant, Midazolam, Enzalutamide
Drug · Combination Product
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
14
States / cities
Los Angeles, California • New Haven, Connecticut • Trumbull, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 20, 2026, 11:21 AM EDT